Oral belzutifan treatment in von hippel-lindau-associated retinal hemangioblastoma: a promising approach
Adnan Kilani, Abdelrahman Assaf, Constantin Jochem, Denise Vogt, Mona Laible, Melih Parlak, Wesam Alkabouni, Armin Wolf · 2026
Read Oral belzutifan treatment in von hippel-lindau-associated retinal hemangioblastoma: a promising approach by Adnan Kilani, Abdelrahman Assaf, Constantin Jochem, Denise Vogt, Mona Laible, Melih Parlak, Wesam Alkabouni, Armin Wolf (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13579817.txt.
Description
Kilani and seven co-authors evaluate oral belzutifan for eye tumors in von Hippel-Lindau disease, in a study from twenty twenty-six. Retinal hemangioblastomas can threaten vision through fluid and bleeding. Local therapies fail in advanced or high-risk lesions sometimes. Five patients with seven eyes receive daily belzutifan after prior treatment failure.
All largest lesions shrink, with median area reduction near fifty-eight percent. Most lesions regress by more than twenty percent overall. Fluid-related detachment resolves in three of four affected eyes. Side effects stay mostly mild to moderate and manageable. Prospective trials must confirm this systemic option's value.
Catalog record
| CREATOR | Adnan Kilani, Abdelrahman Assaf, Constantin Jochem, Denise Vogt, Mona Laible, Melih Parlak, Wesam Alkabouni, Armin Wolf |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |